Retatrutide vs GLP-1 Agonists: Emerging Research on Triple-Hormone Peptides
PeptaBase Research Review | 2026-02-06
Introduction
Retatrutide is an experimental peptide that hits three hormone receptors at once: GLP-1, GIP, and glucagon. Traditional GLP-1 drugs hit just one. Early clinical trials are testing whether this triple approach works better for metabolism and weight.
More detailed pharmacokinetic data can be found on the PeptaBase entry: Retatrutide entry on PeptaBase
Understanding GLP-1 Signaling
GLP-1 drugs work on appetite, insulin, and blood sugar. Well-known examples:
- Semaglutide
- Tirzepatide
- Retatrutide
They all work through the same metabolic hormone system.
Triple-Hormone Signaling
Retatrutide activates three pathways:
- GLP-1 signaling
- GIP signaling
- Glucagon signaling
The theory: hitting three targets at once might produce stronger or wider metabolic effects than hitting just one.
Research Evidence
Early trials track metabolic markers, blood sugar, and body composition. Studies are ongoing and retatrutide is still experimental.
Research Protocol Observations
Clinical trials measure metabolic changes over multiple weeks. Details are on PeptaBase: Retatrutide entry on PeptaBase
Limitations
Retatrutide is still in development. Long-term data doesn't exist yet.